T. Rowe Price Associates
ORIC icon

T. Rowe Price Associates’s Oric Pharmaceuticals ORIC Stock Holding History

T. Rowe Price Associates’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.3M Buy
5,387,783
+2,092,661
+64% +$23.8M 0.01% 701
2025
Q4 		$27M Buy
3,295,122
+423,795
+15% +$4.88M ﹤0.01% 988
2025
Q3 		$34.5M Buy
2,871,327
+108,412
+4% +$1.14M ﹤0.01% 907
2025
Q2 		$28M Buy
2,762,915
+1,430,055
+107% +$9.6M ﹤0.01% 885
2025
Q1 		$7.44M Buy
1,332,860
+37,835
+3% +$331K ﹤0.01% 1166
2024
Q4 		$10.5M Buy
1,295,025
+180,140
+16% +$1.65M ﹤0.01% 1144
2024
Q3 		$11.4M Sell
1,114,885
-74,342
-6% -$735K ﹤0.01% 1120
2024
Q2 		$8.41M Sell
1,189,227
-377,509
-24% -$3.38M ﹤0.01% 1134
2024
Q1 		$21.5M Buy
1,566,736
+915,175
+140% +$10.9M ﹤0.01% 959
2023
Q4 		$6M Buy
651,561
+606,446
+1,344% +$4.39M ﹤0.01% 1171
2023
Q3 		$274K Sell
45,115
-17,949
-28% -$147K ﹤0.01% 2372
2023
Q2 		$490K Buy
63,064
+3,725
+6% +$21.2K ﹤0.01% 2143
2023
Q1 		$339K Hold
59,339
– – ﹤0.01% 2288
2022
Q4 		$350K Hold
59,339
– – ﹤0.01% 2315
2022
Q3 		$191K Buy
59,339
+6,900
+13% +$27.6K ﹤0.01% 2558
2022
Q2 		$235K Sell
52,439
-11,221
-18% -$44.8K ﹤0.01% 2536
2022
Q1 		$340K Buy
63,660
+15,891
+33% +$143K ﹤0.01% 2502
2021
Q4 		$702K Buy
+47,769
New +$745K ﹤0.01% 2217

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's ORIC Position: Q1 2026 in Review

T. Rowe Price Associates increased its Oric Pharmaceuticals (ORIC) stake by 64% in Q1 2026, buying an estimated $23.8M and bringing the position to 5,387,783 shares worth $68.3M. The position accounts for 0.01% of the portfolio, ranked #701.

T. Rowe Price Associates first reported a position in ORIC in Q4 2021 and has held it in 18 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • T. Rowe Price Associates held 5,387,783 shares of Oric Pharmaceuticals worth $68.3M as of Q1 2026.
  • T. Rowe Price Associates bought 2,092,661 Oric Pharmaceuticals shares in Q1 2026, an estimated $23.8M.
  • Oric Pharmaceuticals made up 0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #701 holding.
  • T. Rowe Price Associates first reported a position in Oric Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.